These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32095520)

  • 1. A mutation-independent CRISPR-Cas9-mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency.
    Wang L; Yang Y; Breton C; Bell P; Li M; Zhang J; Che Y; Saveliev A; He Z; White J; Latshaw C; Xu C; McMenamin D; Yu H; Morizono H; Batshaw ML; Wilson JM
    Sci Adv; 2020 Feb; 6(7):eaax5701. PubMed ID: 32095520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Exon-Specific Small Nuclear U1 RNA (ExSpeU1) Improves Hepatic OTC Expression in a Splicing-Defective
    Balestra D; Ferrarese M; Lombardi S; Ziliotto N; Branchini A; Petersen N; Bosma P; Pinotti M; van de Graaf SFJ
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33228018
    [No Abstract]   [Full Text] [Related]  

  • 3. AAV-encoded OTC activity persisting to adulthood following delivery to newborn spf(ash) mice is insufficient to prevent shRNA-induced hyperammonaemia.
    Cunningham SC; Kok CY; Spinoulas A; Carpenter KH; Alexander IE
    Gene Ther; 2013 Dec; 20(12):1184-7. PubMed ID: 24108150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice.
    Yang Y; Wang L; Bell P; McMenamin D; He Z; White J; Yu H; Xu C; Morizono H; Musunuru K; Batshaw ML; Wilson JM
    Nat Biotechnol; 2016 Mar; 34(3):334-8. PubMed ID: 26829317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction and prevention of severe hyperammonemia in the spfash mouse model of ornithine transcarbamylase deficiency using shRNA and rAAV-mediated gene delivery.
    Cunningham SC; Kok CY; Dane AP; Carpenter K; Kizana E; Kuchel PW; Alexander IE
    Mol Ther; 2011 May; 19(5):854-9. PubMed ID: 21386824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AAV2/8-mediated correction of OTC deficiency is robust in adult but not neonatal Spf(ash) mice.
    Cunningham SC; Spinoulas A; Carpenter KH; Wilcken B; Kuchel PW; Alexander IE
    Mol Ther; 2009 Aug; 17(8):1340-6. PubMed ID: 19384294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of a clinical candidate AAV8 vector for ornithine transcarbamylase (OTC) deficiency reveals functional enzyme from each persisting vector genome.
    Wang L; Morizono H; Lin J; Bell P; Jones D; McMenamin D; Yu H; Batshaw ML; Wilson JM
    Mol Genet Metab; 2012 Feb; 105(2):203-11. PubMed ID: 22133298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term correction of ammonia metabolism and prolonged survival in ornithine transcarbamylase-deficient mice following liver-directed treatment with adeno-associated viral vectors.
    Moscioni D; Morizono H; McCarter RJ; Stern A; Cabrera-Luque J; Hoang A; Sanmiguel J; Wu D; Bell P; Gao GP; Raper SE; Wilson JM; Batshaw ML
    Mol Ther; 2006 Jul; 14(1):25-33. PubMed ID: 16677864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AAV gene therapy corrects OTC deficiency and prevents liver fibrosis in aged OTC-knock out heterozygous mice.
    Wang L; Bell P; Morizono H; He Z; Pumbo E; Yu H; White J; Batshaw ML; Wilson JM
    Mol Genet Metab; 2017 Apr; 120(4):299-305. PubMed ID: 28283349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained correction of OTC deficiency in spf( ash) mice using optimized self-complementary AAV2/8 vectors.
    Wang L; Wang H; Morizono H; Bell P; Jones D; Lin J; McMenamin D; Yu H; Batshaw ML; Wilson JM
    Gene Ther; 2012 Apr; 19(4):404-10. PubMed ID: 21850052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recapitulation of Skewed X-Inactivation in Female Ornithine Transcarbamylase-Deficient Primary Human Hepatocytes in the FRG Mouse: A Novel System for Developing Epigenetic Therapies.
    Cunningham SC; van Dijk EB; Zhu E; Sugden M; Mandwie M; Siew S; Devanapalli B; Tolun AA; Klein A; Wilson L; Aryamanesh N; Gissen P; Baruteau J; Bhattacharya K; Alexander IE
    Hum Gene Ther; 2023 Sep; 34(17-18):917-926. PubMed ID: 37350098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction of ornithine transcarbamylase deficiency in adult spf(ash) mice and in OTC-deficient human hepatocytes with recombinant adenoviruses bearing the CAG promoter.
    Kiwaki K; Kanegae Y; Saito I; Komaki S; Nakamura K; Miyazaki JI; Endo F; Matsuda I
    Hum Gene Ther; 1996 May; 7(7):821-30. PubMed ID: 8860834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional characterization of the spf/ash splicing variation in OTC deficiency of mice and man.
    Rivera-Barahona A; Sánchez-Alcudia R; Viecelli HM; Rüfenacht V; Pérez B; Ugarte M; Häberle J; Thöny B; Desviat LR
    PLoS One; 2015; 10(4):e0122966. PubMed ID: 25853564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of tumors arising in male B6C3F1 mice with and without AAV vector delivery to liver.
    Bell P; Moscioni AD; McCarter RJ; Wu D; Gao G; Hoang A; Sanmiguel JC; Sun X; Wivel NA; Raper SE; Furth EE; Batshaw ML; Wilson JM
    Mol Ther; 2006 Jul; 14(1):34-44. PubMed ID: 16682254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corticosteroid suppresses urea-cycle-related gene expressions in ornithine transcarbamylase deficiency.
    Imoto K; Tanaka M; Goya T; Aoyagi T; Takahashi M; Kurokawa M; Tashiro S; Kato M; Kohjima M; Ogawa Y
    BMC Gastroenterol; 2022 Mar; 22(1):144. PubMed ID: 35346058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotype-Phenotype Correlations in Ornithine Transcarbamylase Deficiency: A Mutation Update.
    Caldovic L; Abdikarim I; Narain S; Tuchman M; Morizono H
    J Genet Genomics; 2015 May; 42(5):181-94. PubMed ID: 26059767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OTC gene in ornithine transcarbamylase deficiency: clinical course and mutational spectrum in seven Korean patients.
    Lee JH; Kim GH; Yoo HW; Cheon CK
    Pediatr Neurol; 2014 Sep; 51(3):354-359.e1. PubMed ID: 25011434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo assessment of mutations in OTC for dominant-negative effects following rAAV2/8-mediated gene delivery to the mouse liver.
    Ginn SL; Cunningham SC; Zheng M; Spinoulas A; Carpenter KH; Alexander IE
    Gene Ther; 2009 Jun; 16(6):820-3. PubMed ID: 19357713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive characterization of ureagenesis in the spf
    Allegri G; Deplazes S; Rimann N; Causton B; Scherer T; Leff JW; Diez-Fernandez C; Klimovskaia A; Fingerhut R; Krijt J; Kožich V; Nuoffer JM; Grisch-Chan HM; Thöny B; Häberle J
    J Inherit Metab Dis; 2019 Nov; 42(6):1064-1076. PubMed ID: 30714172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient mitochondrial import of newly synthesized ornithine transcarbamylase (OTC) and correction of secondary metabolic alterations in spf(ash) mice following gene therapy of OTC deficiency.
    Zimmer KP; Bendiks M; Mori M; Kominami E; Robinson MB; Ye X; Wilson JM
    Mol Med; 1999 Apr; 5(4):244-53. PubMed ID: 10448647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.